-+ 0.00%
-+ 0.00%
-+ 0.00%

PROTARA THERAPEUTICS RECEIVES BOTH FDA BREAKTHROUGH THERAPY AND FAST TRACK DESIGNATIONS FOR TARA-002 IN PEDIATRIC PATIENTS WITH LYMPHATIC MALFORMATIONS

Reuters·01/05/2026 13:00:03

Please log in to view news